BPC 157 for Acute Hamstring Muscle Strain Repair

This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing and functional recovery after an acute grade II hamstring muscle strain. Participants will receive BPC 157 or placebo for 14 days in addition to a standardized rehabilitation program. The co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14.

NCT Number	NCT07437547
Lead Sponsor	Hudson Biotech
Conditions	Hamstring Muscle Strain, Skeletal Muscle Injury
Enrollment	120 participants
Start Date	2026-02-02
Primary Completion	2027-02-14 (estimated)
Study Completion	2028-02-17 (estimated)
Updated on ClinicalTrials.gov	2026-02-27